Nikkei Industry Sector
Pharmaceuticals
Overview
Japan's pharmaceutical sector includes both large domestic-focused drug makers and globally operating biopharmaceutical companies with significant international revenue. The industry combines deep scientific capability with strong regulatory relationships and a large aging domestic patient population that drives consistent baseline demand.
Current Trend
Japanese pharma companies are accelerating globalization through overseas acquisitions, licensing deals, and co-development partnerships—particularly in oncology and rare diseases. Biosimilar manufacturing, leveraging Japan's precision production expertise, is also emerging as a significant growth opportunity as biologic patents expire globally.
Companies in This Sector
9
Today's Avg. Price Change
+1.39%
Simple average of constituent stock price changes vs. previous close. Not a sector index.
Updated: 2026-10-30 (JST)
Position in Japan
Japan is the world's third-largest pharmaceutical market by value, providing a stable and substantial home base. The National Health Insurance system, while exerting downward pricing pressure through biennial drug price revisions, ensures broad market access for approved therapies and a predictable revenue floor.
Latest Press Releases
21
Aug
Otsuka Holdings Co.,Ltd. JP3188220002
2026-08-20 Otsuka Holdings Co.,Ltd. “"SOYJOY Matcha & Yuzu" New Release: A rich and flavorful matcha is complemented by the vibrant taste of yuzu.”
21
Aug
Otsuka Holdings Co.,Ltd. JP3188220002
2026-08-20 Otsuka Holdings Co.,Ltd. “Zipalertinib Plus Chemotherapy First-Line Phase 3 REZILIENT3 Trial Data Selected for Presidential Symposium Presentation at the IASLC 2026 World Conference on Lung Cancer (Link to Taiho Oncology's English page).”
21
Aug
Otsuka Holdings Co.,Ltd. JP3188220002
2026-08-20 Otsuka Holdings Co.,Ltd. “"SOYJOY Matcha & Yuzu" New Release: A rich and flavorful matcha is complemented by the vibrant taste of yuzu.”
19
Aug
Eisai Co.,Ltd. JP3160400002
2026-08-18 Eisai Co.,Ltd. “Eisai CEO Haruo Naito and Eisai were honored by Washington University School of Medicine in St. Louis for their long-standing contributions to Alzheimer's disease research and healthcare.”
19
Aug
CHUGAI PHARMACEUTICAL CO.,LTD. JP3519400000
2026-08-18 CHUGAI PHARMACEUTICAL CO.,LTD. “Chugai Pharmaceutical and GSK have signed an exclusive licensing agreement for the anti-dengue virus antibody "AID351".”
18
Aug
Otsuka Holdings Co.,Ltd. JP3188220002
2026-08-17 Otsuka Holdings Co.,Ltd. “Otsuka Pharmaceutical Factory has obtained manufacturing and marketing approval for the V₂-receptor antagonist tolvaptan OD tablets 30mg "Otsuka".”
18
Aug
DAIICHI SANKYO COMPANY,LIMITED JP3475350009
2026-08-17 DAIICHI SANKYO COMPANY,LIMITED “An announcement regarding the approval of Enhertu® and pertuzumab combination therapy for first-line treatment of HER2-positive breast cancer in China (264KB) will open in a new window as a PDF file.”
18
Aug
DAIICHI SANKYO COMPANY,LIMITED JP3475350009
2026-08-17 DAIICHI SANKYO COMPANY,LIMITED “The results of the Phase 3 clinical trial of trastuzumab deruxtecan (T-DXd/DS-8201) for the first-line treatment of non-small cell lung cancer with HER2 gene mutations (270.9KB) will be displayed in a new window as a PDF file.”
15
Aug
CHUGAI PHARMACEUTICAL CO.,LTD. JP3519400000
2026-08-14 CHUGAI PHARMACEUTICAL CO.,LTD. “Tecentriq has submitted an application for expanded indication as adjuvant therapy after surgery for colon cancer with high microsatellite instability (MSI-High).”
14
Aug
Otsuka Holdings Co.,Ltd. JP3188220002
2026-08-13 Otsuka Holdings Co.,Ltd. “In an interim analysis of the Phase III REZILIENT3 trial in the group receiving diparereltinib in combination with chemotherapy for first-line treatment of non-small cell lung cancer with EGFR exon 20 insertion mutations, the primary endpoint of progression-free survival was achieved.”
14
Aug
Sumitomo Pharma Co.,Ltd. JP3495000006
2026-08-13 Sumitomo Pharma Co.,Ltd. “Announcement of the first transplant to a subject in the Phase 1/2 trial of "Retinitis Pigmentosa Treatment using Allogeneic iPS Cell-Derived Retinal Sheet (3D Retina)" in the United States.”
13
Aug
Sumitomo Pharma Co.,Ltd. JP3495000006
2026-08-12 Sumitomo Pharma Co.,Ltd. “Regarding the report concerning our company (our response to "Sumitomo Chemical and Sumitomo Pharmaceutical: Part II – CiRA, Dr. Yamanaka, and the undisclosed history of image duplication concerns").”
08
Aug
CHUGAI PHARMACEUTICAL CO.,LTD. JP3519400000
2026-08-07 CHUGAI PHARMACEUTICAL CO.,LTD. “Chugai Pharmaceutical and the University of California, San Francisco (UCSF) have signed a basic agreement for joint research on drug discovery – establishing a framework to smoothly advance individual research projects.”
08
Aug
Shionogi & Co.,Ltd. JP3347200002
2026-08-07 Shionogi & Co.,Ltd. “A survey of consumers and doctors nationwide regarding their use of AI and medical consultations when experiencing cold symptoms.”
08
Aug
Sumitomo Pharma Co.,Ltd. JP3495000006
2026-08-07 Sumitomo Pharma Co.,Ltd. “Regarding the report about our company (additional explanation regarding "Sumitomo Chemical and Sumitomo Pharmaceutical: The ¥116 Billion Swiss Shuffle").”
08
Aug
Astellas Pharma Inc. JP3942400007
2026-08-07 Astellas Pharma Inc. “Fezolinent has been submitted for manufacturing and marketing approval in Japan as a treatment for vasomotor symptoms associated with menopause.”
06
Aug
Shionogi & Co.,Ltd. JP3347200002
2026-08-05 Shionogi & Co.,Ltd. “Regarding the commencement of verification of support for the decision-making process using TalkLab KIBIT.”
06
Aug
Astellas Pharma Inc. JP3942400007
2026-08-05 Astellas Pharma Inc. “First quarter financial results for fiscal year 2026.”
05
Aug
Otsuka Holdings Co.,Ltd. JP3188220002
2026-08-04 Otsuka Holdings Co.,Ltd. “VOYXACT® (sibeprenelimab), a treatment for IgA nephropathy, has released 2-year eGFR (estimated glomerular filtration rate) data from a Phase 3 trial – demonstrating the potential to stabilize the rate of kidney function decline within the age-appropriate range and fundamentally alter disease progression.”
05
Aug
Otsuka Holdings Co.,Ltd. JP3188220002
2026-08-04 Otsuka Holdings Co.,Ltd. “Otsuka Pharmaceutical is sponsoring the 20th Asian Games (2026/Aichi, Nagoya) and will support conditioning and performance with its global brand "Pocari Sweat".”